Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 7, Pages 1743
Publisher
MDPI AG
Online
2020-04-14
DOI
10.3390/molecules25071743
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
- (2019) Wei Diao et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
- (2019) Cristina Müller et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- PREDICTORS OF OVERALL AND DISEASE FREE SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS RECEIVING 225Ac-PSMA-617 RADIOLIGAND THERAPY
- (2019) Mike Sathekge et al. JOURNAL OF NUCLEAR MEDICINE
- Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle
- (2019) B. Frigerio et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer
- (2019) Sangeeta Ray Banerjee et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer
- (2019) Cristina Müller et al. EJNMMI Research
- Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.
- (2019) Cattrini et al. Cancers
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
- (2019) Meghan A. Rice et al. Frontiers in Oncology
- Past, Current, and Future of Immunotherapies for Prostate Cancer
- (2019) Adeline N. Boettcher et al. Frontiers in Oncology
- 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
- (2019) Fadi Khreish et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer
- (2018) Joey Dacula Mangadlao et al. ACS Nano
- PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer
- (2018) Marie-Christine Heinrich et al. BMC CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Current perspectives on bone metastases in castrate-resistant prostate cancer
- (2018) Christopher Logothetis et al. CANCER AND METASTASIS REVIEWS
- Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
- (2018) Philipp Nuhn et al. EUROPEAN UROLOGY
- Recent Advances in Prostate Cancer Treatment and Drug Discovery
- (2018) Ekaterina Nevedomskaya et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection
- (2018) Lukas M. Carter et al. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy
- (2018) Christoph A. Umbricht et al. MOLECULAR PHARMACEUTICS
- Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators
- (2018) Ján Kozempel et al. MOLECULES
- Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group
- (2018) Andrea K. Miyahira et al. PROSTATE
- STEAP2 Knockdown Reduces the Invasive Potential of Prostate Cancer Cells
- (2018) Stephanie E. A. Burnell et al. Scientific Reports
- Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion
- (2018) Mingzhi Han et al. NEOPLASIA
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
- (2018) Mike Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies
- (2018) Akira Joraku et al. ANNALS OF NUCLEAR MEDICINE
- Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
- (2017) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates
- (2017) Lorenza Scarpa et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
- (2017) Mike Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- STEAP4: its emerging role in metabolism and homeostasis of cellular iron and copper
- (2017) Rachel T Scarl et al. JOURNAL OF ENDOCRINOLOGY
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA Ligands for PET Imaging of Prostate Cancer
- (2017) Sarah M. Schwarzenboeck et al. JOURNAL OF NUCLEAR MEDICINE
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
- (2017) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Glu-Ureido–Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- (2017) Klaus Kopka et al. JOURNAL OF NUCLEAR MEDICINE
- PET imaging of 64 Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs
- (2017) Patty Wong et al. NUCLEAR MEDICINE AND BIOLOGY
- Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer
- (2017) Madhav P. Yadav et al. NUCLEAR MEDICINE COMMUNICATIONS
- A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen
- (2017) Saima Nawaz et al. NUCLEAR MEDICINE COMMUNICATIONS
- Monobodies and other synthetic binding proteins for expanding protein science
- (2017) Fern Sha et al. PROTEIN SCIENCE
- Prostate stem cell antigen is expressed in normal and malignant human brain tissues
- (2017) Hiroe Ono et al. Oncology Letters
- Antagonizing effects of membrane-acting androgens on the eicosanoid receptor OXER1 in prostate cancer
- (2017) Konstantina Kalyvianaki et al. Scientific Reports
- PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer
- (2017) Orielyz Flores et al. Theranostics
- Simple, mild, one-step labelling of proteins with gallium-68 using a tris(hydroxypyridinone) bifunctional chelator: a 68Ga-THP-scFv targeting the prostate-specific membrane antigen
- (2017) Saima Nawaz et al. EJNMMI Research
- Phase II trial of 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu- J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC)
- (2017) S. T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).
- (2017) S. T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Reactor production of Thorium-229
- (2016) Susan Hogle et al. APPLIED RADIATION AND ISOTOPES
- Large scale accelerator production of 225 Ac: Effective cross sections for 78–192 MeV protons incident on 232 Th targets
- (2016) J.R. Griswold et al. APPLIED RADIATION AND ISOTOPES
- Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
- (2016) Min Yuen Teo et al. CANCER JOURNAL
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy
- (2016) U. Haberkorn et al. CLINICAL CANCER RESEARCH
- Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
- (2016) Yana Dekempeneer et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Study of 223Ra uptake mechanism by Fe3O4 nanoparticles: towards new prospective theranostic SPIONs
- (2016) Olga Mokhodoeva et al. JOURNAL OF NANOPARTICLE RESEARCH
- Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
- (2016) Shozo Okamoto et al. JOURNAL OF NUCLEAR MEDICINE
- First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
- (2016) N. Pandit-Taskar et al. JOURNAL OF NUCLEAR MEDICINE
- Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
- (2016) K. Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted -Particle Radiopharmaceutical Therapy
- (2016) A. P. Kiess et al. JOURNAL OF NUCLEAR MEDICINE
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- (2016) A. Afshar-Oromieh et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- (2016) H. R. Kulkarni et al. JOURNAL OF NUCLEAR MEDICINE
- Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer
- (2016) Matthias M. Heck et al. JOURNAL OF UROLOGY
- Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
- (2016) Melanie Hohberg et al. MOLECULAR IMAGING AND BIOLOGY
- Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer
- (2016) Maroor Raghavan Ambikalmajan Pillai et al. NUCLEAR MEDICINE AND BIOLOGY
- Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer
- (2016) Clemens Kratochwil et al. SEMINARS IN NUCLEAR MEDICINE
- Diagnostic and Therapeutic Strategies for Prostate Cancer
- (2016) Mary Nguyen-Nielsen et al. SEMINARS IN NUCLEAR MEDICINE
- PSMA PET and Radionuclide Therapy in Prostate Cancer
- (2016) Kirsten Bouchelouche et al. SEMINARS IN NUCLEAR MEDICINE
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
- (2016) Wolfgang P. Fendler et al. Oncotarget
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
- (2016) Hojjat Ahmadzadehfar et al. Oncotarget
- [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer
- (2015) Clemens Kratochwil et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
- (2015) Andreas Delker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen
- (2015) A. P. Kiess et al. JOURNAL OF NUCLEAR MEDICINE
- A Novel 111In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
- (2015) K. L. S. Chatalic et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
- (2015) M. Weineisen et al. JOURNAL OF NUCLEAR MEDICINE
- Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
- (2015) C. Zhu et al. MOLECULAR CANCER THERAPEUTICS
- Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2
- (2015) Seung-Hwan Park et al. PLoS One
- Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
- (2015) Hojjat Ahmadzadehfar et al. EJNMMI Research
- A role for STEAP2 in prostate cancer progression
- (2014) Helen Whiteland et al. CLINICAL & EXPERIMENTAL METASTASIS
- Targeting human prostate cancer with111In-labeled D2B IgG, F(ab′)2and Fab fragments in nude mice with PSMA-expressing xenografts
- (2014) Susanne Lütje et al. Contrast Media & Molecular Imaging
- Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer
- (2014) Mehdi Evazalipour et al. Contrast Media & Molecular Imaging
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
- (2014) Christian M. Zechmann et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate cancer relevant antigens and enzymes for targeted drug delivery
- (2014) Ashutosh Barve et al. JOURNAL OF CONTROLLED RELEASE
- Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody
- (2014) S. M. Knowles et al. JOURNAL OF NUCLEAR MEDICINE
- Evaluation of Prostate-Specific Membrane Antigen as an Imaging Reporter
- (2014) M. A. Castanares et al. JOURNAL OF NUCLEAR MEDICINE
- Prospective carriers of 223Ra for targeted alpha particle therapy
- (2014) J. Kozempel et al. JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
- Therapeutic radionuclides in nuclear medicine: current and future prospects
- (2014) Chai-Hong Yeong et al. Journal of Zhejiang University-SCIENCE B
- Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
- (2014) Nerissa Therese Viola-Villegas et al. MOLECULAR PHARMACEUTICS
- Development and Characterization of an Antibody-Labeled Super-Paramagnetic Iron Oxide Contrast Agent Targeting Prostate Cancer Cells for Magnetic Resonance Imaging
- (2014) David Bates et al. PLoS One
- Detection and quantitation of glutamate carboxypeptidase II in human blood
- (2014) Tomáš Knedlík et al. PROSTATE
- Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)
- (2014) J. Tykvart et al. PROSTATE
- Design and preclinical evaluation of a 99mTc-labelled diabody of mAb J591 for SPECT imaging of prostate-specific membrane antigen (PSMA)
- (2014) Florian Kampmeier et al. EJNMMI Research
- OXER1, a G protein-coupled oxoeicosatetraenoid receptor, mediates the survival-promoting effects of arachidonate 5-lipoxygenase in prostate cancer cells
- (2013) Sivalokanathan Sarveswaran et al. CANCER LETTERS
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer
- (2013) B. Frigerio et al. EUROPEAN JOURNAL OF CANCER
- Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications
- (2013) Xueling Yang et al. Expert Review of Anticancer Therapy
- Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs
- (2013) Susan F Slovin Immunotherapy
- Functionalized NaA nanozeolites labeled with 224,225Ra for targeted alpha therapy
- (2013) Agata Piotrowska et al. JOURNAL OF NANOPARTICLE RESEARCH
- Anti-Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular -Particle Therapy of Cancer
- (2013) A. Bandekar et al. JOURNAL OF NUCLEAR MEDICINE
- Alpha-Particle Emitting 213Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
- (2013) Christian Wulbrand et al. PLoS One
- Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
- (2013) Scott T. Tagawa et al. Frontiers in Oncology
- PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy
- (2012) Zhihang Chen et al. ACS Nano
- A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
- (2012) M. J. Morris et al. ANNALS OF ONCOLOGY
- Structure-Function of the G Protein–Coupled Receptor Superfamily
- (2012) Vsevolod Katritch et al. Annual Review of Pharmacology and Toxicology
- The STEAP protein family: Versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions
- (2012) Thomas G. P. Grunewald et al. BIOLOGY OF THE CELL
- Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles
- (2012) Benjamin B. Kasten et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Availability of Yttrium-90 from Strontium-90: A Nuclear Medicine Perspective
- (2012) Rubel Chakravarty et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy
- (2012) Xin Gao et al. International Journal of Nanomedicine
- Advances in Immuno–Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology
- (2012) Scott M. Knowles et al. JOURNAL OF CLINICAL ONCOLOGY
- STEAP Proteins: From Structure to Applications in Cancer Therapy
- (2012) I. M. Gomes et al. MOLECULAR CANCER RESEARCH
- Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy
- (2011) You Ling et al. BIOMATERIALS
- Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells
- (2011) Lokman Varisli et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- In Vitro and In Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Antibody to Prostate-Specific Membrane Antigen
- (2011) X. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody
- (2011) J Schwartz et al. PHYSICS IN MEDICINE AND BIOLOGY
- Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
- (2011) Rute B. Marques et al. PLoS One
- An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors
- (2010) Eric J. Lepin et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Gold Nano-Popcorn-Based Targeted Diagnosis, Nanotherapy Treatment, and In Situ Monitoring of Photothermal Therapy Response of Prostate Cancer Cells Using Surface-Enhanced Raman Spectroscopy
- (2010) Wentong Lu et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
- (2009) S. M. Hillier et al. CANCER RESEARCH
- Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen
- (2009) U. Elsasser-Beile et al. CURRENT DRUG TARGETS
- FN3: a new protein scaffold reaches the clinic
- (2009) Laird Bloom et al. DRUG DISCOVERY TODAY
- Prostate stem cell antigen: A prospective therapeutic and diagnostic target
- (2008) Adam B. Raff et al. CANCER LETTERS
- Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice
- (2008) A Lespagnol et al. CELL DEATH AND DIFFERENTIATION
- Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen-Expressing Tumors
- (2008) J. V. Leyton et al. CLINICAL CANCER RESEARCH
- Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
- (2008) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer
- (2008) K. P. Maresca et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen
- (2008) Tiancheng Liu et al. PROSTATE
- Therapeutic Radionuclides: Biophysical and Radiobiologic Principles
- (2008) Amin I. Kassis SEMINARS IN NUCLEAR MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started